BofA lowered the firm’s price target on Werewolf Therapeutics (HOWL) to $9 from $10 and keeps a Buy rating on the shares. While stating that “there wasn’t much new from Werewolf’s 1Q print,” the firm still sees reasons to be encouraged about the second half outlook, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOWL:
- Werewolf Therapeutics Receives Nasdaq Deficiency Notice
- Strategic Expansion and Clinical Potential of Werewolf Therapeutics’ PREDATOR Platform Boosts Buy Rating
- Werewolf Therapeutics price target lowered to $6 from $8 at Wedbush
- Werewolf Therapeutics Reports Q1 2025 Financial Results
- Werewolf Therapeutics files $150M mixed securities shelf